Sign In
Buy APTX
$0.0960
+0 (+0%)
At Close: Mar 28, 2024
Aptinyx to Present at the 39th Annual J.P. Morgan Healthcare Conference
08:30am, Monday, 21'st Dec 2020
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx Appoints Andy Kidd, M.D., President and Chief Operating Officer
08:30am, Wednesday, 16'th Dec 2020
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript
10:11pm, Thursday, 12'th Nov 2020
Aptinyx Inc (APTX) CEO Norbert Riedel on Q3 2020 Results - Earnings Call Transcript
Aptinyx to Participate in Upcoming Virtual Investor Conferences
08:37am, Tuesday, 10'th Nov 2020
EVANSTON, Ill.--(BUSINESS WIRE)--EVANSTON, Ill., November 10, 2020 – Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of
Aptinyx to Report Third Quarter Financial Results on Thursday, November 12, 2020
08:37am, Thursday, 29'th Oct 2020
EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to
Piper Sandler Initiates Coverage On Aptinyx On PTSD Candidate
01:35pm, Tuesday, 27'th Oct 2020
The market's skepticism around Aptinyx Inc's (NASDAQ: APTX) post-traumatic stress disorder (PTSD) candidate appears overdone, according to Piper Sandler. The Aptinyx Analyst: Christopher Raymond initi
3 Top Healthcare Stocks Under $5
07:00am, Tuesday, 27'th Oct 2020
"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.
Aptinyx Announces Pricing of Public Offering of Common Stock
12:00am, Thursday, 22'nd Oct 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
12:00am, Wednesday, 21'st Oct 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 20)
Aileron Therapeutics Inc (...
Aptinyx Announces Proposed Public Offering of Common Stock
12:00am, Tuesday, 20'th Oct 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
Bespoke Beauty Brands, LLC Expands Leadership With Appointment of Brandyn Muegge as President of Sales and Marketing
12:00am, Thursday, 08'th Oct 2020
Bespoke Beauty Brands, LLC Expands Leadership with Appointment of Brandyn Muegge As President of Sales & Marketing
Aptinyx Recommences Patient Recruitment in Phase 2 Study of NYX-2925 in Patients with Fibromyalgia
12:00am, Monday, 28'th Sep 2020
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous sys
Virios Therapeutics Seeks IPO For Fibromyalgia Pain Treatment
07:30am, Tuesday, 15'th Sep 2020
Virios Therapeutics has filed to raise $34.5 million in an IPO of its common stock. The firm is developing a treatment for fibromyalgia, a nerve pain condition.
Aptinyx (APTX) Investor Presentation - Slideshow
04:15pm, Sunday, 16'th Aug 2020
The following slide deck was published by Aptinyx Inc. in conjunction with this event..
